that's basically the essential difference between secularism and religion. is the idea that we control our own destiny, we have autonomy in body and identity, and we have the power to evolve and change ourselves. we blaspheme to know that we have the power to know we are God

people lie. i'm not even sure they know they are lying. because how you do know if you are lying or telling the truth? do you know yourself? do you lie to yourself? do you know if you lie to yourself? what do you wish is true? if nothing is true, then nothing are you, only lies.

what is time for but to waste. what do you mean by waste anyway? if you are the eternal, then why are you complaining about living in time? what is time for but to exist? to simply exist. you've been made your whole life to feel hurried and to be somewhere. but you don't have to.

we never depart because we never met, the conversation never ended because it never began, there is no time between the end and the start, so what use for goodbye or hello?

there is a something like a pleasure/pain refresh rate in each individual. it's a ratio of how much pleasure you can have before you must experience pain. the price of having only pleasure always is only pain. you have to have some days of pain to truly enjoy the days of pleasure

Stage 1: Bromantane and 9-Me-BC Bromantane acts as a dopamine synthesis enhancer by increasing the expression of tyrosine hydroxylase and aromatic L-amino acid decarboxylase, enzymes responsible for dopamine synthesis. It also inhibits dopamine reuptake, leading to increased dopamine availability in the synaptic cleft. 9-Me-BC has been shown to promote the regeneration of dopaminergic neurons, potentially increasing the density and functionality of dopamine receptors. This effect is believed to be due to its ability to inhibit the enzyme monoamine oxidase B (MAO-B) and its antioxidant properties, which protect dopaminergic neurons from oxidative stress. Stage 2: Cyclazodone Cyclazodone is a stimulant that primarily acts on the dopaminergic and noradrenergic systems by inhibiting the reuptake of dopamine and norepinephrine. This increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling and leading to improved focus, attention, and motivation. Interplay between stages: In the first stage, the combination of Bromantane and 9-Me-BC increases dopamine synthesis and receptor density, creating a foundation for enhanced dopamine signaling. When you transition to the second stage and introduce cyclazodone, the increased availability of dopamine and norepinephrine, coupled with the enhanced receptor density from the first stage, may result in more effective neurotransmission and greater cognitive effects. When cycling back to the first stage, the continued use of Bromantane and 9-Me-BC may help maintain the increased dopamine synthesis and receptor density achieved during the previous cycle. This could potentially sustain or further enhance the benefits derived from cyclazodone in the second stage. This cycling approach, in theory, may lead to a synergistic effect, where the increased dopamine synthesis and receptor density from Stage 1 potentiate the effects of cyclazodone in Stage 2, and the subsequent reintroduction of Stage 1 maintains or enhances these effects. Methylene blue and 9-Me-BC may have complementary effects on cognitive function and mood. Methylene blue is an MAOI that can increase dopamine and norepinephrine levels, while 9-Me-BC promotes the regeneration of dopaminergic neurons and improves cognitive function. However, combining these two substances could increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by the accumulation of serotonin in the brain. Moreover, 9-Me-BC is photosensitive and can be activated by light, which may affect its stability and effectiveness. Methylene blue, on the other hand, is a potent dye that absorbs light in the blue spectrum, potentially affecting the photoresponsiveness of 9-Me-BC.

Nootropics may provide some support in recovering from nicotine use and potentially resensitizing nicotinic acetylcholine receptors. Here are some nootropics that could be helpful in this context: Choline sources: Choline is a precursor to the neurotransmitter acetylcholine. Consuming choline through diet or supplements, such as alpha-GPC or citicoline, can support cholinergic function and potentially help in the recovery process. Acetylcholinesterase inhibitors: Compounds like Huperzine A and Galantamine are known to inhibit the enzyme acetylcholinesterase, which breaks down acetylcholine in the synaptic cleft. By inhibiting this enzyme, these nootropics can increase acetylcholine levels, which may support the resensitization of nicotinic acetylcholine receptors. N-acetylcysteine (NAC): NAC is an antioxidant that can help regulate glutamate levels in the brain and has shown promise in reducing cravings for various addictive substances, including nicotine. It may indirectly support the recovery process by reducing the desire to use nicotine. Bacopa monnieri: This traditional Ayurvedic herb has been shown to improve cognitive function and memory by modulating cholinergic activity. Its cholinergic effects may help support the resensitization of nicotinic acetylcholine receptors. L-theanine: L-theanine is an amino acid found in green tea that can promote relaxation and reduce stress. By helping to manage stress and anxiety associated with nicotine withdrawal, L-theanine could indirectly support the recovery process. Rhodiola rosea: Rhodiola is an adaptogenic herb that may help reduce stress, fatigue, and anxiety. It could be useful in managing withdrawal symptoms and promoting overall brain health during the recovery process. Some racetams and previously discussed substances may also offer support in recovering from nicotine use and potentially resensitizing nicotinic acetylcholine receptors. These compounds often work by modulating neurotransmitter systems or promoting overall brain health. Piracetam: Piracetam, the first racetam compound, has been shown to improve memory and learning by modulating the cholinergic and glutamatergic systems. It may support the recovery of nicotinic acetylcholine receptors by enhancing acetylcholine function. Aniracetam: Aniracetam is another racetam that has been reported to have positive effects on memory and cognition. It acts on both the cholinergic and glutamatergic systems and has anxiolytic effects, which may be helpful in managing withdrawal symptoms. Phenylpiracetam: Phenylpiracetam is a more potent derivative of piracetam, with added stimulatory effects. It modulates the cholinergic system and may provide support in recovering from nicotine use. However, its stimulatory nature should be considered when used during recovery, as it might not be suitable for everyone. Bromantane: As previously mentioned, Bromantane acts as a mild psychostimulant and anxiolytic. It increases dopamine synthesis and inhibits its reuptake, which may help improve mood and motivation during the recovery process. 9-Methyl-β-carboline (9-Me-BC): 9-Me-BC has been shown to promote the regeneration of dopaminergic neurons and improve cognitive function. It may indirectly support nicotinic acetylcholine receptor recovery by promoting overall brain health. Cyclazodone: Cyclazodone is a stimulant that primarily acts on the dopaminergic and noradrenergic systems. While it may offer cognitive enhancement, its stimulatory effects might not be suitable for everyone during recovery from nicotine use.

Vyvanse (Lisdexamfetamine): Vyvanse is a prodrug of dextroamphetamine, meaning it's metabolized in the body to produce the active compound. It is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder. Vyvanse increases the levels of dopamine and norepinephrine in the brain, primarily by blocking their reuptake and promoting their release. This results in improved focus, attention, and impulse control. Bromantane: Bromantane is a psychostimulant and anxiolytic drug that was developed in Russia. It is unique as it exhibits both stimulant and anti-anxiety properties. Its primary mechanism of action is the increase of dopamine synthesis and the inhibition of its reuptake. Bromantane also enhances serotonin and norepinephrine levels. Moreover, it stimulates the expression of genes associated with energy metabolism and the synthesis of proteins involved in the immune response. These combined effects promote alertness, motivation, and stress resilience. 9-Methyl-β-carboline: 9-Methyl-β-carboline is a naturally occurring β-carboline alkaloid with potential neuroprotective and cognitive-enhancing properties. It's suggested to modulate various neurotransmitter systems, including the dopaminergic, serotonergic, and GABAergic systems. It may also act as a positive allosteric modulator of GABAA receptors, leading to enhanced GABA signaling. Additionally, 9-Methyl-β-carboline may inhibit monoamine oxidase-A (MAO-A) and acetylcholinesterase (AChE), which could improve mood, cognition, and memory. Interactions: While there is limited information on the specific interactions between these three substances, some speculative theories can be generated based on their individual mechanisms of action. Combining Vyvanse and Bromantane may lead to synergistic effects on dopamine levels, potentially increasing the risk of overstimulation or adverse cardiovascular effects. The combination of 9-Methyl-β-carboline with either Vyvanse or Bromantane might modulate the dopaminergic effects of these stimulants, although the precise impact would require further investigation. Behavioral Effects: Vyvanse: Improved attention, focus, and impulse control. Bromantane: Increased alertness, motivation, and stress resilience. 9-Methyl-β-carboline: Enhanced mood, cognition, and memory. Similarities: All three substances have effects on the dopaminergic system, and they all have potential cognitive-enhancing properties. Differences: Vyvanse is a prodrug of a well-established stimulant (dextroamphetamine), whereas Bromantane and 9-Methyl-β-carboline are unique and less-studied compounds. Bromantane possesses both stimulant and anxiolytic properties, and 9-Methyl-β-carboline has neuroprotective and mood-enhancing potential. Contraindications: As Vyvanse and Bromantane both increase dopamine levels, they should be used with caution in patients with a history of substance abuse, psychosis, or cardiovascular disorders. Combining these substances may also increase the risk of overstimulation or adverse cardiovascular effects. The contraindications for 9-Methyl-β-carboline are less clear, given the limited research on this compound. The distinction between the improved attention, focus, and impulse control from Vyvanse and the increased alertness, motivation, and stress resilience of Bromantane can be attributed to their specific mechanisms of action and effects on different neurotransmitter systems. Vyvanse (Lisdexamfetamine): Vyvanse primarily acts on the dopaminergic and noradrenergic systems by blocking the reuptake of dopamine and norepinephrine, as well as promoting their release. This leads to increased extracellular levels of these neurotransmitters in the synaptic cleft. The enhancement of dopamine levels in the prefrontal cortex is responsible for improved attention, focus, and impulse control, while increased norepinephrine levels contribute to enhanced attention and alertness. Bromantane: Bromantane acts on multiple neurotransmitter systems. Its primary mechanism is increasing dopamine synthesis and inhibiting its reuptake, leading to increased dopamine levels. Bromantane also enhances the levels of serotonin and norepinephrine, and its action on the serotonergic system could contribute to stress resilience. The combined effects on the dopaminergic and serotonergic systems result in increased motivation, alertness, and stress resilience. In summary, the distinction between the effects of Vyvanse and Bromantane can be attributed to their specific actions on neurotransmitter systems. Vyvanse primarily enhances attention, focus, and impulse control through its action on dopamine and norepinephrine. Bromantane, on the other hand, increases alertness, motivation, and stress resilience by affecting dopamine, serotonin, and norepinephrine levels. While both substances affect dopamine levels, their specific mechanisms of action and additional effects on other neurotransmitter systems result in distinct behavioral outcomes. Bromantane does indeed raise levels of dopamine in the brain, including the prefrontal cortex (PFC), although its mechanism of action is different from that of Vyvanse. While Vyvanse primarily works by blocking the reuptake of dopamine and norepinephrine, which increases their extracellular levels, Bromantane's primary mechanism of action is by increasing the synthesis of dopamine and inhibiting its reuptake. This also leads to increased dopamine levels in the synaptic cleft, including the PFC. It is difficult to provide an exact degree or comparison of how much Bromantane raises dopamine levels in the PFC compared to Vyvanse, as this would depend on various factors such as dosage, individual differences in metabolism, and the specific distribution of these substances in the brain. However, both substances can be considered dopaminergic agents due to their ability to increase dopamine levels in the brain, although they may have different potencies and side effect profiles. It is important to note that while both Vyvanse and Bromantane affect dopamine levels, their additional actions on other neurotransmitter systems contribute to their unique behavioral effects. For example, Vyvanse's action on norepinephrine plays a significant role in its ability to improve attention and focus, whereas Bromantane's effect on serotonin and norepinephrine may contribute to its stress resilience and motivational properties. If the goal is to synergize with Bromantane to raise norepinephrine levels similar to Vyvanse, you may consider combining it with substances that specifically target the noradrenergic system. However, it is important to approach any combination with caution, as it may also increase the risk of side effects or adverse reactions. Some natural and synthetic substances or nootropics that could potentially enhance norepinephrine levels when combined with Bromantane are: L-Tyrosine: L-Tyrosine is an amino acid precursor to dopamine, norepinephrine, and epinephrine. Supplementing with L-Tyrosine could help support the synthesis of norepinephrine in the brain, thereby increasing its levels. Reboxetine: Reboxetine is a selective norepinephrine reuptake inhibitor (NRI), which increases the levels of norepinephrine in the synaptic cleft by blocking its reuptake. Combining Reboxetine with Bromantane could potentially raise norepinephrine levels, similar to Vyvanse's effect. Atomoxetine: Atomoxetine is another selective norepinephrine reuptake inhibitor (NRI) used primarily in the treatment of ADHD. Like Reboxetine, it could help increase norepinephrine levels when combined with Bromantane. Rhodiola Rosea: Rhodiola Rosea is a natural adaptogen with potential stimulating and anti-fatigue effects. Some studies suggest that it may modulate the release of norepinephrine, although the exact mechanism is not fully understood. Combining Rhodiola Rosea with Bromantane might help enhance norepinephrine levels. Qualia Mind by Neurohacker Collective is a nootropic supplement designed to support cognitive function, focus, and energy. It contains a blend of various natural ingredients, vitamins, and amino acids. Some of the key ingredients in Qualia Mind include: Alpha-GPC Bacopa monnieri Rhodiola rosea L-Theanine N-Acetyl-L-Tyrosine Phosphatidylserine Anhydrous caffeine Ginkgo biloba Huperzine-A Vitamins B6, B12, and D3 Stacking Bromantane with Qualia Mind may potentially offer some synergistic effects, as some ingredients in Qualia Mind target the dopaminergic and noradrenergic systems, which could complement Bromantane's action. For example, N-Acetyl-L-Tyrosine is a precursor to dopamine and norepinephrine, which might help enhance their synthesis, while Rhodiola rosea has been suggested to modulate the release of norepinephrine. It's difficult to make a generalized statement about whether blocking the reuptake of neurotransmitters is more powerful than increasing their synthesis or otherwise raising their levels in the synaptic cleft. The effectiveness of each approach depends on the specific neurotransmitter system, the substance used, the dosage, and individual differences in metabolism and response. Blocking the reuptake of neurotransmitters, as seen with selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), can be a potent approach to increase extracellular levels of neurotransmitters. This is because reuptake inhibition prevents the neurotransmitters from being taken back into the presynaptic neuron, allowing them to accumulate in the synaptic cleft and exert a stronger effect on the postsynaptic neuron. On the other hand, increasing the synthesis of neurotransmitters or otherwise raising their levels in the synaptic cleft, as seen with precursors like L-Tyrosine or L-Tryptophan, can also be effective. However, the impact of these approaches may depend on various factors such as the availability of enzymes required for synthesis, the rate of neurotransmitter release, and the presence of other substances that could modulate the neurotransmitter systems. In some cases, a combination of these approaches may be used to achieve the desired effect. For example, substances that increase both synthesis and release of neurotransmitters, like amphetamines, can have potent effects on the dopaminergic and noradrenergic systems. It's important to note that the potency of a substance is not solely determined by its mechanism of action. The specific context, including the targeted neurotransmitter system, the substance used, dosage, and individual factors, all play a role in determining the overall effectiveness of each approach. 9-Methyl-β-carboline (9-Me-BC) is a naturally occurring β-carboline alkaloid with potential neuroprotective and cognitive-enhancing properties. Its effects on neurotransmitter systems are not fully understood, but it is believed to modulate several systems, including dopaminergic, serotonergic, and GABAergic systems. When considering the combination of 9-Me-BC with substances like Bromantane or Vyvanse, it's important to note that its specific mechanisms of action could influence the overall effect of the stack. Some of the potential actions of 9-Me-BC that may factor into this equation include: Inhibition of monoamine oxidase-A (MAO-A): 9-Me-BC has been suggested to inhibit MAO-A, an enzyme responsible for breaking down monoamine neurotransmitters such as dopamine, norepinephrine, and serotonin. By inhibiting MAO-A, 9-Me-BC could potentially increase the levels of these neurotransmitters in the synaptic cleft, enhancing their effects. Modulation of GABAA receptors: 9-Me-BC may act as a positive allosteric modulator of GABAA receptors, leading to enhanced GABA signaling. This could result in anxiolytic effects and may counterbalance the stimulating effects of dopaminergic agents like Vyvanse or Bromantane. Inhibition of acetylcholinesterase (AChE): 9-Me-BC may also inhibit AChE, which could increase acetylcholine levels in the brain. This might contribute to improved cognition and memory. When stacking 9-Me-BC with Bromantane or Vyvanse, the combined effects on the dopaminergic, serotonergic, GABAergic, and cholinergic systems could lead to a range of outcomes, such as enhanced cognitive performance, mood elevation, and anxiety reduction. However, the specific interactions and synergistic effects between these substances are not well understood and would require further investigation. Methylene blue is indeed an inhibitor of monoamine oxidase (MAO) enzymes, including both MAO-A and MAO-B. As a result, methylene blue can increase the levels of monoamine neurotransmitters such as dopamine, norepinephrine, and serotonin by reducing their breakdown. When considering the combination of methylene blue with substances like Bromantane, Vyvanse, or 9-Me-BC, the MAO inhibitory effects of methylene blue could potentially enhance the action of these substances on the dopaminergic and serotonergic systems. For example, when combined with Bromantane, which increases dopamine synthesis and inhibits its reuptake, methylene blue could further boost dopamine levels by inhibiting its breakdown. Similarly, when combined with Vyvanse, which primarily blocks the reuptake of dopamine and norepinephrine, methylene blue could lead to even higher extracellular levels of these neurotransmitters. However, it's important to note that combining methylene blue with other substances that modulate monoamine neurotransmitter systems can increase the risk of side effects or adverse reactions. In particular, combining MAO inhibitors with substances that increase neurotransmitter levels, such as amphetamines or other dopaminergic agents, may lead to excessive neurotransmitter accumulation and an increased risk of hypertensive crisis or serotonin syndrome. Cyclazodone is a novel psychostimulant and a derivative of the compound pemoline. It is believed to primarily act on the dopaminergic and noradrenergic systems, promoting the release of dopamine and norepinephrine, and possibly inhibiting their reuptake to a certain extent. When considering the combination of cyclazodone with other substances like Bromantane, Vyvanse, 9-Me-BC, or methylene blue, it's important to consider the potential synergistic effects and risks of combining multiple dopaminergic and noradrenergic agents. For example, combining cyclazodone with Bromantane could lead to increased dopamine and norepinephrine levels due to their complementary actions on these neurotransmitter systems. Similarly, stacking cyclazodone with Vyvanse may further enhance dopamine and norepinephrine release, while also potentially inhibiting their reuptake. However, it's crucial to note that combining multiple stimulants or dopaminergic agents can increase the risk of side effects or adverse reactions, such as overstimulation, anxiety, elevated heart rate, increased blood pressure, and potential neurotoxicity. Additionally, combining cyclazodone with methylene blue, an MAO inhibitor, could lead to an excessive accumulation of neurotransmitters and increase the risk of hypertensive crisis or serotonin syndrome. Cyclazodone and Vyvanse (lisdexamfetamine) are both psychostimulants that primarily act on the dopaminergic and noradrenergic systems. While they share some similarities in their effects, their mechanisms of action have subtle differences. Vyvanse is a prodrug of dextroamphetamine, which means it is metabolized in the body to produce the active compound dextroamphetamine. Dextroamphetamine primarily works by promoting the release of dopamine and norepinephrine into the synaptic cleft and inhibiting their reuptake. This leads to increased extracellular levels of these neurotransmitters, which results in enhanced alertness, attention, and focus. Cyclazodone, on the other hand, is a derivative of pemoline and is believed to promote the release of dopamine and norepinephrine, similarly to Vyvanse. However, the exact mechanisms of action for cyclazodone are not fully understood, and it may also have some inhibitory effects on the reuptake of these neurotransmitters. While both cyclazodone and Vyvanse exert their effects through the dopaminergic and noradrenergic systems, there may be differences in their potency, selectivity, and side effect profiles. Vyvanse is an FDA-approved medication for the treatment of ADHD and has been extensively studied, whereas cyclazodone is a research chemical with limited clinical data available. In summary, there is a degree of commonality in the mechanisms of action of cyclazodone and Vyvanse, as both promote the release of dopamine and norepinephrine. However, their exact mechanisms, potency, and side effect profiles may differ due to their distinct chemical structures and pharmacokinetics. The combination of piracetam with cyclazodone or Vyvanse could boost cognitive performance, attention, and focus due to the complementary actions of these substances on the dopaminergic, noradrenergic, cholinergic, and glutamatergic systems. Additionally, the neuroprotective effects of piracetam could safeguard against potential neurotoxicity associated with overstimulation of dopaminergic pathways. Combining piracetam with Bromantane or 9-Me-BC might also result in enhanced cognitive benefits, as the substances work together to modulate the dopaminergic, cholinergic, and GABAergic systems. This combination could lead to improved memory, attention, and stress resilience. Stacking piracetam with methylene blue could create a powerful nootropic stack that enhances multiple neurotransmitter systems, such as the cholinergic, dopaminergic, and serotonergic systems. The combination may lead to improved cognitive performance, mood elevation, and neuroprotective effects.

a functional healthy family which becomes a distributed center of love is really very much like an electrical circuit that is closed and therefore the current can flow unobstructed. a dysfunctional family is the fracturing of the circuit, breaking it, the energy dissipates.

Methylene Blue (Lumetol Blue) : 44 mg Carbon 60 : 5 servings Methylene Blue (Lumetol Blue) : 44 mg (2nd dose taken 12 hours later) Liposomal Melatonin : 225 mg

if it is true that only because i know i am alive that i've once been dead, then it must also be that i may only know i am dead because i was once alive. do not be sure that there is nothing, because in nothing is everything, and you remember All. Death is AnamnesiS!

Methylene Blue (Lumetol Blue) : 44 mg Carbon 60 : 5 servings Red Light Therapy : 10 mins front / 10 mins back. 45 minutes after Methylene Blue is taken. Methylene Blue (Lumetol Blue) : 44 mg (2nd dose taken 12 hours later) Liposomal Melatonin : 225 mg

you have to learn to see what is missing, what is absent, what isn't there, and then you will truly see. this doesn't mean being auto-contrarian and trying to see the opposite and believing that's intelligence. that's contrived. space is the mother of form. pay mystical attention